natgillin/translations-raw huggingface dataset:
to 90 g per litre polyethylene glycol; and 
do 200 g po litri polietilen glikola.
The method comprises: administering an oral sulfate composition to the patient in an amount effective to purge the gastrointestinal tract of the patient of its contents and to cleanse the gastrointestinal tract, the oral sulfate composition being a transit speed enhancer and comprising an sulfate in the form of an inorganic sulfate salt and not containing a phosphate salt; orally administering an activated capsule endoscope to the patient; positioning a receiver to detect data transmitted from the activated capsule endoscope as it passes through the interior of gastrointestinal tract of the patient; and analyzing the data detected by the receiver before and/or after the administered capsule endoscope has been expelled from the colon of the patient. 
PATENTNI ZAHTJEVI Upotreba oralne otopine sulfata, naznačena time što je namijenjena pripremi gastrointestinalnog sustava pacijenta za pregled unutrašnjosti gastrointestinalnog sustava pacijenta kapsulom endoskopijom, gdje oralnu otopinu sulfata treba primijeniti na pacijentu u količini koja djelotvorno prazni gastromtestinalni sustav pacijenta od njegovog sadržaja 1 čisti gastrointestinalni sustav, i gdje je oralna otopina sulfata ubrzivač vremena prolaska, sadrži natrijev sulfat, kalijev sulfat, te magnezijev sulfat, sadrži otprilike 0,0096 g/ml do otprilike 0,50 g/ml sulfata u obliku anorganske sulfatne soli, te ne sadrži fosfatnu sol.
characterised in that the step of combusting the spent mushroom compost comprises combusting the spent mushroom compost in a fluidised bed unit (37); 
naznačeno time, što korak termičke obrade otpada od peradi obuhvaća spaljivanje otpada od peradi u jedinici s fluidiziranim slojem.
A combination for use according to claim 9, wherein the active compound (c) is selected from the group consisting of (a) PDE IV inhibitors and (b) cortiocosteroids. 
Kombinacija sukladno patentnom zahtjevu 9, naznačena time, da je djelatni spoj (c) odabran iz skupine koja se sastoji od (a) inhibitora PDE IV i (b) kortikosteroida.
A clear and homogeneous solution comprising two or more polymers and a lipophilic active compound in an aqueous solvent in single phase that does not undergo sedimentation or precipitation, wherein at least one of the two or more polymers is an amphiphilic polymer and at least another of the two or more polymers is either a hydrophilic polymer or an amphiphilic polymer with a hydrophobic-hydrophilic balance different from the first amphiphilic polymer. 
(i) pripremanje bistre i homogene otopine dva ili više polimera i najmanje jednog lipofilnog aktivnog spoja u smjesi vode i organskog otapala; i (ii) sušenje bistre i homogene otopine polimera-lipofilnog aktivnog spoja (1) za formiranje suhog praha; pri čemu vodenasta otopina ima najmanje 50% težinski vode i sušenje u koraku (ii) se provodi sušenjem raspršivanjem.
The method as in any one of the preceding embodiments, wherein the method further comprises the step of applying cellulose fibers, preferably alpha cellulose fibers, on the paper, before heating the décor (8). 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje metoda dalje sadrži korak nanošenja vlakana celuloze, poželjno vlakana alfa celuloze, na papir, prije zagrijavanja dekora (8).
the at least one active immunogenic component is derived from a pathogen selected from Adenoviridae, Parvoviridae, Coronaviridae, Herpesviridae, Poxviridae, Rhabdoviridae, and combinations thereof; or 
(a) porijeklom od patogena koji sadrži Adenoviridae, Parvoviridao, Coronaviridae, Herpesviridae, Poxviridao, Rhabdoviridae ili njihove kombinacije ili
The dosage can range depending on the age and general conditions of the patient, nature and severity of the disease or disorder and route and type of administration. 
Doza se može mijenjati ovisno o dobi i općim uvjetima pacijenta, prirodi 1 ozbiljnosti bolesti ili poremećaja ili načinu i tipu davanja.
The invention relates particularly to a method of preparing B-glucan, protein, starch and lipid concentrates from oat, the method comprising the following steps of: 
HR P20140065 T1 PATENTNI ZAHTJEVI Postupak pripreme koncentrata B-glukana, proteina, škroba i lipida iz zobi, naznačen time što obuhvaća korake:
is chosen from hydrogen, alkyl, aryl, alkylaryl, substituted alkyl, substituted aryl, and substituted alkylaryl; and 
je odabran između vodika, alkila, arila, alkilarila, supstituiranog alkila, supstituiranog arila, i supstituiranog alkilarila; i
a DNA-targeting segment comprising a nucleotide sequence that is complementary to a sequence in a target DNA, and a protein-binding segment that interacts with said Cas9 polypeptide, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, and wherein said two complementary stretches of nucleotides are covalently linked by intervening nucleotides, and 
(i) segment koji ciljana DNA, koji sadrži nukleotidni slijed komplementaran slijedu u ciljanoj DNA, 1 (ii) segment koji se veže na proteine koji međudjeluje s navedenim polipeptidom Cas9, gdje segment koji se veže na proteine sadrži dva komplementarna odsječka nukleotida koji hibridiziraju kako bi tvorili dvolančani RNA (dsRNA) dupleks; i gdje
Wind system (1) according to claim 7, characterised in that said permanent magnets are neodymium iron boron magnets. 
Vjetreni sustav (1) prema zahtjevu 14, naznačen time da spomenuti prijenosni sustav uključuje:
orally administering an activated capsule endoscope to the patient; positioning a receiver to detect data transmitted from the activated capsule endoscope as it passes through the interior of gastrointestinal tract of the patient; and analyzing the data detected by the receiver before and/or after the administered capsule endoscope has been expelled from the colon of the patient; or the oral sulfate solution for the use of claim 8, wherein determining the source, type, location, and cause of the gastrointestinal pathology in the patient comprises orally administering an activated capsule endoscope to the patient; 
Upotreba u skladu s patentnim zahtjevom 6, naznačena time što se određivanje izvora, vrste, lokacije, te uzroka gastrointestinalne patološke pojave kod pacijenta sastoji u oralnoj primjeni aktiviranog kapsularnog endoskopa na pacijentu; smještavanju prijemnika koji detektira i sprema podatke koje šalje kapsularni endoskop dok prolazi kroz intestinal sustav pacijenta; i analiziranju podataka koje je detektirao prijemnik prije i/ii nakon izbacivanja primijenjenog kapsularnog endoskopa iz debelog crijeva pacijenta, gdje podaci ukazuju na vrstu, lokaciju i uzrok patološke pojave.
The process of claim 1, wherein in step c) the extended release matrix formulation is subjected to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least about 5 minutes. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1, naznačen time da formulacija matrice s produljenim otpuštanjem kada je podvrgnuta indentacijskom testu ima „dubinu prodiranja s razmakom pukotine“ od barem oko 1.0 mm.
The anti-cancer vaccine according to claim 6, wherein said adjuvant is selected from the group of colony-stimulating factors, such as Granulocyte Macrophage Colony Stimulating Factor (GM- CSF). 
Farmaceutski sastav sukladno tvrdnji 15, pri čemu se spomenuto pomoćno sredstvo odabire iz skupine kolonija stimulativnih faktora, kao što je granulocit makrofag kolonija stimulativni faktor (3GM-CSF).
A compound of Formula IA: wherein A is aryl, or heteroaryl; 
Spoj formule IA: [image] naznačen time da A je aril ili heteroaril;
The method of claim 13, wherein the disease is psoriasis. 
Spoj prema zahtjevu 1 za upotrebu prema zahtjevu 13, naznačen time da je bolest psorijaza.
The front post according to claims 1 and 4, characterized in that said cross-member (8) is forced against said lateral wing (3a) of said front post (1). 
Prednji podupirač prema patentnom zahtjevu 3, naznačen time, da navedeni poprečni element (8) silom pritišće na navedeno bočno krilo (34) spomenutog prednjeg podupirača (1).
the peptide is covalently linked to the targeting moiety and/or 
nanočestica sadrži ciljani dio na površini, pri čemu je peptid opcijski kovalentno vezan na ciljnu skupinu;
The assembly as recited in claim 6 wherein said thermal switch comprises a bi-metal material. 
Sklop na način opisan u Zahtjevu 4 pri čemu navedeni termalni prekidač (935) sadrži bimetalni materijal.
The pyridine derivative or the pharmaceutically acceptable salt thereof, according to claim 5, wherein R3 is a hydrogen atom, a methyl group, an ethyl group, an isopropyl group, a cyclopropyl group, a chlorine atom, a bromine atom, an iodine atom, a trifluoromethyl group, a difluoromethyl group, a methoxy group, a phenyl group, a cyano group, a carboxyl group, —CO2R5, a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxypropan-2-yl group, a 3-hydroxypentan-3-yl group, a dimethylaminomethyl group, or a diethylaminomethyl group. 
HR P20180451 T1 Derivat piridina ili njegova farmaceutski prihvatljiva sol, ili njegov solvat prema zahtjevu 9, naznačen time da Rz je vodikov atom, metilna skupina, etilna skupina, izopropilna skupina, ciklopropilna skupina, klorov atom, bromov atom, jodov atom, trifluorometilna skupina, difluorometilna skupina, metoksi skupina, fenilna skupina, cijano skupina, acetilna skupina, karboksilna skupina, -CO>R5, hidroksimetil skupina, 1-hidroksietil skupina, 2hidroksipropan-2-il skupina, 3-hidroksipentan-3-il skupina, dimetilaminometil skupina, dietilaminometilna skupina, ili morfolin-4-ilmetil skupina.
The preferred application rates of the active ingredients of the optional component C) are compiled in the following table. 
Poželjne stope primjene aktivnih sastojaka izborne komponente C) su navedene u slijedećoj tablici.
FIG. 5 is a section of the top and the sidewalls of lid from point G to H of FIG. 
Slika 5 - prikazuje presjek gornjeg dijela i bočnih stijenki poklopca od točke G do H.
an inhibitor of neutrophil serine proteases, such as neutrophil elastase or proteinase 3. 
* inhibitor neutrofil serin proteaza, na primjer neutrofilne elastaze ili proteinaze 3.
Pirfenidone for use in treating a patient according to aspect I, wherein, prior to step (a), said patient is administered pirfenidone at doses lower than 1600 mg/day for a time period. 
Pirfenidon za upotrebu u liječenju pacijenta prema zahtjevu 1, gdje se prije stupnja (a) spomenutom pacijentu daje pirfenidon u dozama manjim od 1600 mg/dan u tijeku vremenskog perioda.
When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or fatty oil. 
Kada je oblik jedinice doziranja kapsula, ona uz materijale gore navedenog tipa može sadržavati i tekuću podlogu, poput polietilen-glikola ili masnog ulja.
(100 mL) and stirred at room temperature for 4h. 
(100 ml) i miješa na sobnoj temperaturi kroz 4 sata.
Data of the technical literature show that in case of the readily water-soluble venlafaxine hydrochloride experts have so far failed to elaborate a composition of the excipients enabling the preparation of pellets having a high active ingredient content and a suitable quality (being approximately spherical in shape) and providing an advantageous product fraction. 
Podaci iz tehničke literature pokazuju da u slučaju lako topljivog venlafaksin hidroklorida eksperti još nisu uspjeli razraditi smjesu ekscipijenata koja omogućuje priređivanje granula s visokim sadržajem aktivnog sastojka i odgovarajuće kakvoće (približno kuglastog oblika) uz visoku frakciju produkta.
Use of a compound according to any of claims 1 to 26 in the manufacture of a medicament for the treatment or the prevention of diseases or disorders linked to abnormal physiological behaviour of inorganic ion receptors and in particular of the calcium receptor. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 26 naznačen time da je za proizvodnju lijeka za liječenje ili sprečavanje bolesti ili poremećaja povezanih sa nenormalnim fiziološkim ponašanjem anorganskih ionskih Teceptora 1 naročito receptora kalcija.
A speech decoding method executed by a speech decoding device to decode an encoded speech signal, the speech decoding method comprising: 
Program za dekodiranje govora, namijenjen dekodiranju kodiranog govornog signala, naznačen time što omogućuje da kompjutorska naprava funkcionira kao:
a second formulation comprising a binding agent in an effective amount to covalently bind free thiol groups in hair, wherein the binding agent is represented by Formula I: wherein 
(b) drugu formulaciju koja sadrži sredstvo za vezanje u učinkovitoj količini da se kovalentno veže za slobodne tiolne skupine u kosi, pri čemu je sredstvo za vezanje prikazano formulom I
Figure 3 is a transverse sectional view of a portion of a variation of said first embodiment of the shoe, according to the invention; 
Slika 3 je prikaz poprečnog presjeka dijela navedenog prvog utjelovljenja cipele sukladno predmetnom izumu;
A compound according to claim 23 wherein the NSAID subunit is of indomethacin. 
Spoj u skladu s patentnim zahtjevom 22, gdje nesteroidna protuupalna podjedinica je indometacin.
a mechanical treatment which is selected from a treatment with a mixer, a treatment with an homogenizer, and a treatment with a mill; and/or 
mehaničke obrade koja je odabrana od tretmana s mikserom, tretmana s homogen i zatorom i tretmana s mlinom; i/ili
a valve device (7) arranged so as to control the selective opening and closing off of the supply system sections (5, 6); 
Upravljački uređaj koji ima peristaltički ventil za upravljanje selektivnim otvaranjem i zatvaranjem prve i druge elastične cijevi (5, 6, 50, 60) koje prolaze kroz uređaj, pri čemu navedeni uređaj sadržava:
providing an adjacent surface (13, 14) to said substrate (12), 
- priprema susjedne površine (13, 14) za navedeni supstrat (12),
A composition as claimed in any one of Claims 1 to 20 or 30, wherein the amount of phospholipid in the composition is from 17 (±10%) mg/mL to 70 (±10%) mg/mL. 
Kompozicija prema bilo kojem od zahtjeva 1 do 20 ili 30, naznačena time što je količina fosfolipida u kompoziciji od 17 (±10%) mg/ml do 70 (±10%) mg/ml.
Alternatively, spraying system 10 could be in movement as the agricultural crop is also moving. 
Alternativno, sustav 10 za raspršivanje može se pomicati kada se i poljoprivredni usjev pomiče.
A process for producing an organic amine salt of 6-fluoro-3-hydroxy-2-pyrazinecarbonitrile according to claim 1, which comprises reacting 3,6-difluoro-2-pyrazinecarbonitrile with water in the presence of a base, and then forming a salt with an organic amine, wherein the organic amine is dicyclohexylamine. 
Postupak za proizvodnju organske aminske soli 3-hidroksi-2-pirazinkarbonitrila u skladu s patentnim zahtjevom 1, naznačen time, da se sastoji od reakcije 3,6-difluoro-2-pirazinkarbonitrila s vodom u nazočnosti lužine, a potom formiranja soli s organskim aminom, pri čemu je organski amin dicikloheksilamin. da je organski amin
wherein the extended release matrix formulation is cured at a temperature of at least about 60 °C for a time period of at least about 1 minute and has a cracking force of at least about 110 N when subjected to an indentation test. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem koji sadrži formulaciju matrice sa produljenim otpuštanjem koji je stvrdnut na temperaturi od najmanje oko 60 °C tijekom vremenskog perioda od najmanje oko 1 minute, te formulacija matrice s produljenim otpuštanjem sadrži pripravak koji je naznačen time da sadrži barem:
E -3-[4'-chlorobiphenyl-4-yl]-N-hydroxy-acrylamide. A process for preparing the compounds according to claim 1 or 2 comprising reacting the corresponding carboxylic acids with hydroxylamine hydrochloride. 
Postupak za pripremanje spojeva prema zahtjevu 1 ili 2, naznačen time, što uključuje reakciju odgovarajućih karbonskih kiselina sa hidroksilamin-hidrokloridom.
The method of claim 1, wherein the pH during cultivation at the first temperature and/or the second temperature is between 6 and 8. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je pH tijekom uzgoja na prvoj temperaturi 1/ili drugoj temperaturi između 6 i 8.
for studs, windows. 
za stupove, prozore.
Subsequently, the pellet is resuspended in 20 mM Hepes + I mM EDTA, pH 7.4 and homogenized with a 50- ml Dounce homogenizer and again centrifuged. 
Neposredno zatim, peleta je bila resuspendirana u 20 mM Hepes + 1 mM EDTA, pH 7.4 i homogenizirana sa 50-ml Dounce homogenizatorom i ponovno centrifugirana.
or a salt thereof; reacting the compound of formula (IV), or a salt thereof, with N-hydroxysuccinimide in the presence of a base to form a salt of the compound of formula (V); and 
(M ili njegova sol; b) reakciju spoja formule (IV), ili njegove soli, s N-hidroksisukcinimidom u prisutnosti baze, da se dobije sol spoja s formulom (V); i
A "mammal" is an individual animal that is a member of the taxonomic class Mammalia. 
"Sisavac" je jedinka koja je član takonomskog razreda Mammalia (sisavci).
The ophthalmic aqueous solution according to claim 1, wherein the PGF2a analogue is latanoprost. 
Oftalmološka vodena otopina prema zahtjevu 1, gdje oftalmološka vodena otopina je jedinična doza ili jedinični dozni spremnik koji se u bitnome sastoji od polietilena niske gustoće.
The method of claim 1, wherein the concentration of glycine is in the range of from 10 mM to 25 mM, or 15 mM to 20 mM, or 16 mM to 18 mM. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je koncentracija glicina u rasponu od 10 mM do 25 mM, ili 15 mM do 20 mM ili 16 mM do 18 mM.
The antibody, immunoconjugate, pharmaceutical composition, bispecific or multispecific molecule or expression vector for use according to claim 24, wherein the one or more further therapeutic agents are selected from a chemotherapeutic agent, an antiinflammatory agent, or an immunosuppressive and/or immunomodulatory agent. 
Protutijelo, imunokonjugat, farmaceutski pripravak, bispecifična ili multispecifična molekula za uporabu u skladu s patentnim zahtjevom 22, naznačena time, da se jedno ili više daljnjih terapijskih sredstava odabire između kemoterapeutskog sredstva, protuupalnog sredstva ili imunosupresivnog i / ili imunomodulacijskog sredstva.
Particularly, one embodiment includes a method of increasing the amount of a protein of interest wherein the protein of interest is rFVIII available for recovery from a sample containing other components and following a first purification step of the sample comprising: exposing a positively charged depth filter through which the sample has been passed to a salt elution buffer wherein exposure to the elution buffer releases the protein of interest from the filter for subsequent recovery, wherein the salt elution buffer has a conductivity of at least 20 mg/cm. 
HR P20171272 T1 PATENTNI ZAHTJEVI Metoda za povećanje količine proteina od interesa dostupnog za iskorištenje iz uzorka koji sadrži druge sastavnice 1 koja slijedi prvi korak pročišćavanja uzorka obuhvaća: izlaganje pozitivno nabijenog dubinskog filtra kroz koji je uzorak prošao soli elucijskog pufera pri čemu izlaganje elucijskom puferu oslobađa protem od interesa iz filtra za sljedeće iskorištenje, pri čemu sol elucijskog pufera ima provodljivost od najmanje 20 mS/cm.
The conjugate of claim 7, wherein said Taxol molecules are conjugated through the N-terminal amine group and through the amine groups on the lysines at positions 10 and 15 of the Angiopep-2 sequence. 
Konjugat prema zahtjevu 5, naznačen time da su navedene molekule Taxola konjugirane kroz N-terminalni kraj aminske skupine i kroz aminske skupine na lizinima na položajima 10 1 15 u Angiopep-2 sekvenci.
A suitable base is, for example, an organic amine base such as, for example, di-isopropylethylamine, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, N- methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or for example, an alkali metal or alkaline earth metal carbonate or hydroxide, for example sodium carbonate, potassium carbonate, cesium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide. 
Prikladna baza je, na primjer, organski amin, npr. diizopropiletilamin, = piridin, 2,6-lutidin, kolidin, = 4-dimetilaminopiridin, = tri-etilamin, - N-metilmorfolin ili diazabiciklo[5.4.0] undec-7-en, ili na primjer, karbonat ili hidroksid alkalijskih ili zemnoalkalijskih metala, npr. natrij- karbonat, kalij-karbonat, cezij-karbonat, kalcij-karbonat, natrij-hidroksid, ili kalij-hidroksid.
wherein the agent for treatment of hypertension is an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, diuretic, beta-blocker, or calcium channel blocker; or 
(c) sredstvo za liječenje hipertenzije je inhibitor enzima za pretvaranje angiotenzina, blokator receptora angiotenzina II, diuretik, beta-blokator, ili blokator kanala kalcija; ili
The metal substrate of claim 7, comprising another electroplated metal layer containing embedded luminescent particles of a different composition than the previous embedded luminescent particles. 
Metalna podloga u skladu s patentnim zahtjevom 7, naznačena time što ima drugi galvanizirani metalni sloj, koji sadrži uklopljene luminiscentne čestice drugačijeg sastava nego ranije uklopljene luminiscentne čestice.
A compound for use in the treatment of an inflammation that is associated with a metabolic disorder, an inflammatory bowel disease, a neurodegenerative disorder, or a muscular wasting disorder, wherein the compound is a compound of formula I: or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, or stereoisomer thereof, wherein: 
11. Spoj, naznačen time što je namijenjen upotrebi u liječenju upale povezane s metaboličkim poremećajem, upalnom bolesti crijeva, neurodegenerativnim poremećajem ili poremećajem propadanja mišića, gdje je spoj spoj formule I:
Ra, Rb, Rc and Rd are independently selected from H and (1-3C)alkyl, or Rc and Rd are independently selected from H and (1-3C)alkyl, and Ra and Rb together with the atom to which they are attached form a cyclopropyl ring; 
R*, R", R" i R" su neovisno odabrani od H i (1-3C)alkil, ili Ri R" su neovisno odabrani od H i (1-3C)alkil, i R* i R" zajedno s atomom na koji su oni vezani tvore ciklopropilni prsten;
R6, at each occurrence, is independently alkyl or cycloalkyl; or wherein: 
, uvijek kada se pojavljuje, je nezavisno alkil ili cikloalkil; ili gdje:
an autoimmune disease wherein the autoimmune disease is bullous skin disorder and wherein said bullous skin disorder is pemphigus vulgaris (PV) or bullous pemphigoid (BP) 
Spoj ili sol prema zahtjevu 52 naznačen time da navedeni bulozni kožni poremećaj je pemfigus vulgaris (PV) ili bulozni pemfigoid (BP).
A compound of formula (I) wherein 
Spoj s formulom (I) pri čemu